Actively Recruiting
MAX - SHOCK Clinical Trial
Led by Ottawa Heart Institute Research Corporation · Updated on 2026-02-03
376
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Can Electrical Cardioversion (ECV) for AF be improved. It is the preferred method to restore sinus rhythm in patients with AF in whom a rhythm-control strategy is pursued. Hypothesis: ECV success rates will be greater with a biphasic defibrillator with maximum energy of 360J (® Physio-Control) compared to a biphasic defibrillator with maximum energy of 200J (® Zoll)
CONDITIONS
Official Title
MAX - SHOCK Clinical Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients age > 18 years
- Persistent atrial fibrillation
- Scheduled for elective cardioversion at UOHI
- Patient is within the circle of care of UOHI Electrophysiology staff
You will not qualify if you...
- Known left-atrial appendage thrombus
- Contraindication to appropriate anticoagulation
- Patient is included in another randomized clinical trial
- Patient does not meet all of the above listed inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Actively Recruiting
Research Team
T
Tammy Knight
CONTACT
D
David Birnie
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here